A Phase I, Ascending Multiple-dose Clinical Trial of CSPCHA115 Capsules to Evaluate the Tolerability and Pharmacokinetics in Chinese Healthy Volunteers
Latest Information Update: 30 Apr 2021
At a glance
- Drugs CSPCHA 115 (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CSPC Pharmaceutical Group
- 26 Apr 2021 Status changed from not yet recruiting to completed.
- 10 Nov 2019 Status changed from planning to not yet recruiting.
- 16 Jul 2018 New trial record